Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367664 | 0.93 | MAPT (0.48) | MAPTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL15329329 | 0.91 | KCNH2 (0.46) | KCNH2MAPTPOLBMEN1KMT2A | |
| SCHEMBL2367584 | 0.89 | MAPT (0.54) | MAPTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2367982 | 0.87 | HSD17B10 (0.54) | MAPTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2367082 | 0.87 | KCNH2 (0.47) | KCNH2MAPTPOLBMEN1KMT2A | |
| SCHEMBL1923550 | 0.84 | KDM4E (0.49) | KCNH2MAPTPOLBMEN1KMT2A | |
| SCHEMBL2367784 | 0.84 | MEN1 (0.46) | MAPTPOLBMEN1KMT2AMAPK1 | |
| SCHEMBL2390141 | 0.83 | KCNH2 (0.38) | KCNH2MAPTPOLBMEN1KMT2A | |
| SCHEMBL15329816 | 0.83 | PTGDR2 (0.48) | MAPTPOLBPTGDR2SMN1; SMN2TSHR | |
| SCHEMBL3754549 | 0.83 | MAPT (0.42) | KCNH2MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | claimed |
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | claimed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | claimed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | claimed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | claimed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | claimed |
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009060053-A1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | KCNH2 974/4885MAPT 118/4885POLB 2172/4885 |
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | KCNH2 974/4885MAPT 118/4885POLB 2172/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | KCNH2 974/4885MAPT 118/4885POLB 2172/4885 |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FASN | KCNH2 4310/4885MAPT 3320/4885POLB 3739/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | KCNH2 974/4885MAPT 118/4885POLB 2172/4885 |
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | KCNH2 1176/4885MAPT 3475/4885POLB 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.